Detection and measurement of thyroid analyte profile

• US 7,794,954 B2
• Filed: 04/24/2009
• Issued: 09/14/2010
• Est. Priority Date: 11/12/2008
• Status: Active Grant

• Current Assignee: Hemopet
• Original Assignee: Hemopet
• Inventors: Dodds, W. Jean, Ongchangco, Ferdie S.
• Primary Examiner(s): Yu; Melanie J.
• Assistant Examiner(s): Counts; Gary W
• Application Number:
  US12/430,038
• Publication Number:
  US 20100120168A1
• Time in Patent Office: 508 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: G01N 2800/046 Thyroid disorders
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors

Abstract

A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. A non-radioisotopic method detects Free T4 in a sample of a non-human species.

Claims

1. A non radioisotopic method of determining canine T4AA in a patient sample comprising:

(a) measuring the amount of Free T4 in a patient sample, wherein the sample is from a canine species, the Free T4 being attached as Free T4/T4AA complex when T4AA is present in the patient sample together with Free T4 unattached to T4AA;

(b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind Free T4/T4AA complex thereby forming a complex of precipitated or bound Free T4/T4AA complex;

(c) suspending the non-radioisotopic precipitate or bound complex, and at least one of;

(i) measuring the amount of Free T4/T4AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label, and

(ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of Free T4/T4AA complex thereby determining the amount of T4AA in the patient sample;

or

(iii) measuring Free T4 in supernatant or surrounding fluid of the non-radioisotopic precipitate or bound complex using a non-radioisotopic label;

(iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of Free T4/T4AA complex thereby determining the amount of T4AA in the patient sample;

effecting detection with a sensitivity in a range between 1 picogram per mL and up to about 1 femtogram per mL.

9. The method as claimed in claim 1 including having a specificity of the assay at a level at least as specific as an assay performed by known radioimmunoassay technique.

2. A non radioisotopic method of determining canine T4AA in a sample:

(a) measuring the amount of Free T4 in a patient sample, wherein the sample is from a canine species, the Free T4 being attached as Free T4/T4AA complex when T4AA is present in the patient sample together with Free T4 unattached to T4AA;

(b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind Free T4/T4AA complex thereby forming a complex of precipitated or bound FreeT4 and T4AA;

(c) suspending the non-radioisotopic precipitate or bound complex, and at least one of;

(i) measuring the amount of Free T4/T4AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label; and

(ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of Free T4/T4AA complex thereby determining the amount of T4AA in the patient sample;

or

(iii) measuring Free T4 in supernatant or surrounding fluid of the precipitate or bound complex using a non-radioisotopic label; and

(iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of FreeT4/T4AA complex thereby determining the amount of T4AA in the patient sample; and

effecting detection of a), c) i) or c) iii) by employing non-radioisotopic chemiluminesence, and including a bioluminescent detector and microparticles for immobilizing Free T4 as a solid phase, thereby to obtain a non-radioisotopic determination of T4AA.

7. The method as claimed in claim 2 the detection range being with a sensitivity between 1 picogram per mL and up to about 1 femtogram per mL.

10. The method as claimed in claim 2 including effecting detection by detecting with a sensitivity range between 1 picogram per mL and up to 1 femtogram per mL, and having a specificity of the assay at a level at least as specific as an-assay performed by known radioimmunoassay technique.

12. The method as claimed in claim 2 including measuring Free T4 by both of steps i) and ii) and steps iii) and iv).

3. A non radioisotopic method of determining canine T4AA in a sample:

(a) measuring the amount of Free T4 in a patient sample, wherein the sample is from a canine species, the Free T4 being attached as Free T4/T4AA complex when T4AA is present in the patient sample together with Free T4 unattached to T4AA;

(b) treating the patient sample with a non-radioisotopic precipitating or binding agent to precipitate or bind FreeT4/T4AA complex thereby forming a complex of precipitated or bound FreeT4 and T4AA;

(c) suspending the non-radioisotopic precipitate or bound complex, and at least one of;

(i) measuring the amount of Free T4/T4AA complex in suspended non-radioisotopic precipitate or bound complex using a non-radioisotopic label, and

(ii) subtracting the measurement of i) from a) wherein the result of ii) is directly proportional to the amount of FreeT4/T4AA complex thereby determining the amount of T4AA in the patient sample;

or

(iii) measuring Free T4 in supernatant or surrounding fluid of the precipitate or bound complex using a non-radioisotopic label; and

(iv) subtracting the measurement of iii) from a) wherein the result of iv) is indirectly proportional to the amount of FreeT4/T4AA complex thereby determining the amount of T4AA in the patient sample; and

(d) effecting detection of a), c) i) or c) iii) by employing a non-radioisotopic detection thereby to obtain a non-radioisotopic determination of T4AA.

4. The method as claimed in claim 3 including measuring Free T4 by both of steps i) and ii) and steps iii) and iv).

5. The method as claimed in claim 3 including measuring, in the step of c) i) T4AA complex in the precipitate or a detachable bound complex, or in the step of c) iii), the Free T4, the measuring being by fluorescence, chemical or other tagging, or measuring the mass.

6. The method as claimed in claim 3 including employing direct chemiluminesence, and including a bioluminescent detector and microparticles for immobilizing Free T4 and having a non-radioisotopic label for detection as a solid phase, the detection of the amount of Free T4 being with a sensitivity more than 1 picogram per mL and being a sensitivity of at least up to about 1 femtogram per mL.

8. The method as claimed in claim 3 including effecting detection of T4AA complex of step a), c) i) or the Free T4 of c) iii) by detecting with sensitivity in a range between 1 picogram per mL up to 1 femtogram per mL.

11. The method as claimed in claim 3 including effecting detection by detecting with a sensitivity range between 1 picogram per mL and up to 1 femtogram per mL, and having a specificity of the assay at a level at least as specific as an-assay performed by known radioimmunoassay technique.

13. The method as claimed in claim 3 including measuring Free T4 by both of steps i) and ii) and steps iii) and iv).